

**SUPPLEMENTARY FILE 10: SENSITIVITY ANALYSIS REGROUPING ONE ARM OF GIRLING *ET AL.***

**Odds ratios and relative ranks from fixed- and random-effects network meta-analyses across all isoniazid resistance profiles- one arm of Girling *et al.* 1991 recoded to regimen RIF ED<3 D=6m**

Sensitivity analysis regrouping one treatment arm of Girling *et al.* 1991 [1] from regimen RIF ED≥3 Pr6 D=6m to RIF ED<3 D=6m to reflect uncertainty during categorisation. CrI- credible interval, OR- odds ratio

Treatment	OR (95% CrI)		Rank (95% CrI)	
	Fixed-effects	Random-effects	Fixed-effects	Random-effects
ED<3 D<6m	3.66 (1.12-12.35)	4.74 (0.53-59.53)	11 (8-11)	11 (4-11)
ED<3 D≥6m	2.69 (1.28-5.85)	2.69 (0.68-10.85)	10 (8-11)	9 (5-11)
ED≥3 D≥6m	0.95 (0.37-2.41)	1.01 (0.16-6.73)	6 (3-9)	6 (2-10)
RIF ED<3 D<6m	1.07 (0.57-2.05)	1.45 (0.50-5.95)	6 (4-9)	7 (4-10)
RIF ED<3 D=6m	0.56 (0.26-1.20)	0.62 (0.18-2.19)	3 (2-6)	4 (1-8)
RIF ED<3 D>6m	0.20 (0.03-1.21)	0.22 (0.01-3.87)	1 (1-7)	1 (1-10)
RIF ED<3 Pr6 D=6m	baseline	baseline	6 (3-9)	6 (2-9)
RIF ED<3 Pr6 D>6m	1.04 (0.40-2.67)	0.88 (0.12-5.53)	6 (3-10)	5 (1-10)
RIF ED≥3 D<6m	1.68 (0.59-4.76)	1.99 (0.38-12.28)	9 (4-10)	8 (3-11)
RIF ED≥3 Pr6 D=6m	0.83 (0.02-11.10)	0.97 (0.01-35.60)	5 (1-11)	5 (1-11)
RIF ED≥3 Pr6 D>6m	0.33 (0.12-0.84)	0.48 (0.08-4.67)	2 (1-4)	3 (1-9)

**Odds ratios and relative ranks from fixed- and random-effects network meta-analyses across all isoniazid resistance profiles- one arm of Girling *et al.* 1991 recoded to regimen RIF ED<3 Pr6 D=6m**

Sensitivity analysis regrouping one treatment arm of Girling *et al.* 1991 [1] from regimen RIF ED≥3 Pr6 D=6m to RIF ED<3 Pr6 D=6m (and thereby losing the study from the network, due to both treatment arms being grouped the same) to reflect uncertainty during categorisation. CrI- credible interval, OR- odds ratio

Treatment	OR (95% CrI)		Rank (95% CrI)	
	Fixed-effects	Random-effects	Fixed-effects	Random-effects
ED<3 D<6m	3.44 (1.04-11.86)	4.47 (0.42-67.25)	11 (8-11)	11 (4-11)
ED<3 D≥6m	2.53 (1.18-5.59)	2.50 (0.56-11.64)	10 (8-11)	9 (5-11)
ED≥3 D≥6m	0.91 (0.35-2.33)	0.95 (0.13-7.25)	6 (3-9)	6 (2-10)
RIF ED<3 D<6m	0.99 (0.51-1.96)	1.35 (0.42-6.57)	6 (4-9)	7 (4-10)
RIF ED<3 D=6m	0.48 (0.20-1.14)	0.53 (0.12-2.39)	3 (2-6)	3 (1-8)
RIF ED<3 D>6m	0.17 (0.02-1.08)	0.19 (0.01-4.19)	1 (1-6)	1 (1-10)
RIF ED<3 Pr6 D=6m	baseline	baseline	6 (3-9)	6 (2-10)
RIF ED<3 Pr6 D>6m	1.01 (0.38-2.62)	0.84 (0.11-6.04)	6 (3-10)	5 (1-11)
RIF ED≥3 D<6m	1.58 (0.54-4.53)	1.88 (0.32-13.36)	9 (4-10)	8 (3-11)
RIF ED≥3 Pr6 D=6m	0.77 (0.02-10.43)	0.91 (0.01-41.50)	5 (1-11)	5 (1-11)
RIF ED≥3 Pr6 D>6m	0.31 (0.12-0.81)	0.46 (0.06-5.26)	2 (1-4)	3 (1-10)

**References**

- 1 Girling DJ, Chan SL. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: Results at 30 months. *Am Rev Respir Dis* 1991;143:700-6.